Comparative Pharmacology
Head-to-head clinical analysis: SENSORCAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SENSORCAINE versus XYLOCAINE 4 PRESERVATIVE FREE.
SENSORCAINE vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SENSORCAINE (bupivacaine) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting depolarization and propagation of action potentials, resulting in reversible local anesthesia.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
Epidural or caudal block: 15-30 mL of 0.5% to 1% solution (75-150 mg) every 2-4 hours as needed. Maximum single dose: 225 mg.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
The terminal elimination half-life of bupivacaine is approximately 2.7 hours in adults (range 1.5–5.5 hours). In neonates, the half-life is significantly prolonged (~8–12 hours) due to immature hepatic function, leading to an increased risk of toxicity.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
SENSORCAINE (bupivacaine) is primarily metabolized in the liver via conjugation with glucuronic acid and undergoes hepatic dealkylation. Approximately 6% of the drug is excreted unchanged in the urine. The majority of the dose (about 95%) is excreted as metabolites in the urine (<10% unchanged) and the remainder in feces via biliary elimination.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic